MARKET

CRVS

CRVS

Corvus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.260
+0.260
+8.67%
Closed 16:00 10/15 EDT
OPEN
3.055
PREV CLOSE
3.000
HIGH
3.320
LOW
2.985
VOLUME
74.85K
TURNOVER
--
52 WEEK HIGH
8.90
52 WEEK LOW
2.530
MARKET CAP
95.14M
P/E (TTM)
-2.0903
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CRVS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CRVS News

  • Corvus Pharmaceuticals: Bankruptcy Or Blockbuster
  • Seeking Alpha - Article.17h ago
  • 55 Biggest Movers From Yesterday
  • Benzinga.5d ago
  • The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
  • Benzinga.10/04 11:32
  • Stocks That Hit 52-Week Lows On Thursday
  • Benzinga.10/03 17:03

More

Industry

Biotechnology & Medical Research
+2.02%
Pharmaceuticals & Medical Research
+1.28%

Hot Stocks

Name
Price
%Change

About CRVS

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
More

Webull offers Corvus Pharmaceuticals Inc (CRVS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.